Small molecule-induced protein degradation is an attractive strategy for the development of chemical probes. Protein degraders have the power to abrogate all of the functions of a drug target at once, including scaffolding functions which are difficult to target with small molecule inhibitors. A novel class of PROTACs that incorporate small molecule VHL ligands to successfully degrade HaloTag7 fusion proteins has been developed. HaloPROTACs will inspire the development of future PROTACs with more drug-like properties. In HEK 293 cells stably expressing GFP-HaloTag7, 24 hour treatment with HaloPROTAC1 leads to less than 20% degradation, the longer HaloPROTAC2 leads to nearly 70% degradation of GFP-Halotag7 at 2.5 μM. HaloPROTACs containing protein degrader 1 leads to nearly 70% degradation of GFP-HaloTag7, when sufficiently long linkers are used. VH 032 is a derivative of the von Hippel-Lindau (VHL) ligand, and is commonly used as a precursor to PROTACs that hijack VHL as the E3 ubiquitin ligase component. VH 032 is supplied with a primary amine functional handle at a position known not to significantly affect binding to VHL, for ready conjugation to a linker/target protein ligand.
|Quantity||5 mg, 10 mg, 25 mg|
|Molecular Weight||467.02 g/mol|
|Physical State||Lyophilized white powder|
|Solubility||40 mg/mL in DMSO|
|Storage||solutions at -20°C or -80°C; desiccated at -20°C, avoid freeze/thaw cycles|